TMEM150B

Across TCGA pan-cancer cohorts, TMEM150B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMEM150B data layer compared with 27 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher TMEM150B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM150B expression acts as an unfavorable survival marker.

LUSC, SCLC, and CHOL are the cancer types where TMEM150B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.112	0.733	<.001	18	view →
SCLC	OS	Median	All	0.219	0.706	.011	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TMEM150B–LUSC (OS)

Open the LUSC breakdown →